

[Click here and type address]

facsimile transmittal

To: Materials licensing **Fax:** 630-515-1078

From: Joni Pintado **Date:** 02/17/2009

Re: Antonio Ambrad, MD Authorized user **Pages:** 4

CC:

Urgent For Review Please Comment Please Reply Please Recycle

Notes:

License number 13-02650-02

Because of the emergency nature of a patient needing HDR on 3/2/09, please review at your earliest convenience.

Sincerely,

Joni Pintado,
RSO and AMP



.....



SAINT JOSEPH
Regional Medical
Center

125 Years of Faith Based Healthcare
in Michigan

SOUTH BEND
801 East LaSalle Avenue
South Bend, Indiana 46617
574.237.7111

MISHAWAKA
215 West 4th Street
Mishawaka, Indiana 46544
574.259.2431

PLYMOUTH
1915 Lake Avenue
Plymouth, Indiana 46563
574.936.3181

**SAINT JOSEPH
ADMINISTRATIVE OFFICES**
4215 Edison Lakes Parkway
Mishawaka, Indiana 46545
574.237.7111
574.247.8700 fax

**SAINT JOSEPH
PHYSICIAN NETWORK**
810 East Park Place
Mishawaka, Indiana 46545
574.472.6760
574.472.6774 fax

www.sjmed.com

February 16, 2009

Colleen Carol Casey
United States Nuclear Regulatory Commission
Region III, Licensing Section
2443 Warrenville Road, Ste 210
Lisle, Illinois 60532-4352

Re: USNRC License # 13-02650-02

Dear Ms. Casey:

We have a patient who needs treatment in 2 weeks, 3/2/09. It is medically necessary that we add Antonio J. Ambrad, MD as authorized user for Ir-192 as permitted by 10 CFR 35.600. Please add Antonio J. Ambrad, MD as an authorized user to our license so that we can treat this HDR patient in 2 weeks, 3/2/09.

Enclosed is a copy of his NRC license #37-30477-01 where he is listed as an Authorized user with South Pittsburgh Cancer Center for Ir-192 use.

Respectfully:

Lori Price
Chief Operating Officer
Saint Joseph Regional Medical Center

Joni Pintado
Radiation Safety Officer

NRC FORM 374A

U.S. NUCLEAR REGULATORY COMMISSION

PAGE 2 of 4 PAGES

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License Number
37-30477-01

Docket or Reference Number
030-34832

Amendment No.02

11. Licensed material listed in item 6 above is only authorized for use by, or under the supervision of, the following individuals for the materials and uses indicated:

Authorized Users

Material and Use

Antonio J. Ambrad, M.D.

Iridium 192 for uses in a high dose rate remote afterloading brachytherapy device

12. The Medical Physicists for this license for Item 6.A. are Mitchell Jarosz, Jr., M.S., Amirul Hoque, Ph.D., Michael Rutstein, M.S. and Jagdish P. Bhatnager, Sc.D. The Medical Physicist for this license for Item 6.B. is Amirul Hoque, Ph.D.

13. The Radiation Safety Officer for this license is Antonio J. Ambrad, M.D.

14. A. Access to the treatment room housing each high dose rate remote afterloading brachytherapy unit shall be controlled by a door at each entrance.


B. Each entrance to the treatment room shall be equipped with an electrical interlock system that will cause the source to return to the shielded position immediately upon opening of the entrance door. The interlock system shall be connected in such a manner that the source cannot be placed in the irradiation position until the entrance door is closed and the source "on-off" control is reset at the control panel.

C. Electrical interlocks on each entrance door to the treatment room shall be tested for proper operation at least once each day of use.

D. In the event of malfunction of the door interlock, the unit shall be locked in the "off" position and not used, except as may be necessary for repair or replacement of the interlock system, until the interlock system is shown to be functioning properly.

15. Prior to initiation of a treatment program, and subsequent to each source exchange for each high dose rate remote afterloading brachytherapy unit, a radiation survey shall be made of:

A. The source housing, with the source in the shielded position. The maximum radiation levels at 10 centimeters from the surface of the main source safe shall not exceed 1 millirem per hour.



NRC FORM 374

U.S. NUCLEAR REGULATORY COMMISSION

PAGE 1 OF 4 PAGES
Amendment No. 2

MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 39, 40, and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

<p>Licensee</p> <p>1. South Pittsburgh Cancer Center</p> <p>2. 4941 Clairton Boulevard Pittsburgh, Pennsylvania 15236</p>	<p>In accordance with the letter dated June 21, 2001, and facsimile received July 12, 2001,</p> <p>3. License number 37-30477-01 is amended in its entirety to read as follows:</p> <p>4. Expiration date January 31, 2009</p> <p>5. Docket No. 030-34832 Reference No. A</p>
---	---

<p>6. Byproduct, source, and/or special nuclear material</p> <p>A. Iridium-192</p> <p>B. Iridium 192</p>	<p>Chemical and/or physical form</p> <p>A. Sealed Source (Maljnickrodt Medical B.V. Model 105.002)</p> <p>B. Sealed Source (Ornitrion International Inc. Model SL77)</p>	<p>8. Maximum amount that licensee may possess at any one time under this license</p> <p>A. 2 sources, 1 source not to exceed 12 curies, and 1 source not to exceed 10 curies.</p> <p>B. 2 sources, 1 source not to exceed 12 curies, and 1 source not to exceed 10 curies.</p>
--	--	---

<p>9. Authorized use:</p> <p>A. One source to be used in a Nucletron Corporation MicroSelectron Model 105.999 high dose rate remote afterloading brachytherapy device for interstitial, intraluminal, and intracavitary radiotherapy in humans. The source activity may not exceed 10 curies at the time of installation. One source in its shipping container for source replacement.</p> <p>B. One source to be used in an Ornitrion Model 2000 HDR remote afterloading brachytherapy device for interstitial, intraluminal, and intracavitary radiotherapy in humans. One source in its shipping container for source replacement.</p>

CONDITIONS

10. Licensed material may be used only at the licensee's facilities located at 4941 Clairton Boulevard, Pittsburgh, Pennsylvania.